Findings of Research Misconduct, 22320-22321 [2012-8903]

Download as PDF 22320 Federal Register / Vol. 77, No. 72 / Friday, April 13, 2012 / Notices EARLY TERMINATIONS GRANTED—Continued MARCH 1, 2012 THRU MARCH 31, 2012 20120627 20120628 20120629 20120630 20120632 20120636 20120638 ...... ...... ...... ...... ...... ...... ...... G G G G G G G Wendel SA; Loma International Corporation; Wendel SA. Mercer International Inc.; Fibrek Inc.; Mercer International Inc. Precision Castparts Corp.; RathGibson Holding Co. LLC; Precision Castparts Corp. Audax Private Equity Fund III, L.P.; Brazos Equity Fund III, L.P.; Audax Private Equity Fund III, L.P. Ocwen Financial Corporation; Morgan Stanley; Ocwen Financial Corporation. Wynnchurch Capital Partners III, L.P.; Mueller Water Products, Inc.; Wynnchurch Capital Partners III, L.P. Fertitta Investment LLC; Station Holdco LLC; Fertitta Investment LLC. 03/26/2012 20120569 ...... 20120631 ...... G G Glory Limited; Carlyle Europe Partners III, L.P.; Glory Limited. Nuance Communications, Inc.; Transcend Services, Inc.; Nuance Communications, Inc. 03/27/2012 20120586 ...... 20120649 ...... G G Franz Haniel & Cie. GmbH; G. Thomas Patton, III; Christopher N. Patton; Franz Haniel & Cie. GmbH. Howard Midstream Energy Partners, LLC; EnCap Energy Infrastructure Fund, L.P.; Howard Midstream Energy Partners, LLC. 03/28/2012 20120620 ...... G Golden Gate Capital Opportunity Fund, L.P.; Infor Enterprise Applications Ltd.; Golden Gate Capital Opportunity Fund, L.P. 03/29/2012 20120648 ...... G Mr. Mark Zuckerberg; Mr. Mark Zuckerberg; Mr. Mark Zuckerberg. 03/30/2012 20111374 20120633 20120637 20120644 20120653 20120655 20120657 ...... ...... ...... ...... ...... ...... ...... G G G G G G G Humana Inc.; Arcadian Management Services, Inc.; Humana Inc. OHI Parent, Inc.; Osmose Holdings, Inc.; OHI Parent, Inc. Wellspring Capital Partners V, L.P.; Industrial Growth Partners III, L.P.; L.P. MDCP VI–A Global Investments, LP; Pinafore Investment Cooperatief U.A.; MDCP VI–A Global Investments, LP. Riverside Capital Appreciation Fund V LP; The Riverstone Group, LLC; Fund V LP. Sumitomo Corporation; Midas, Inc.; Sumitomo Corporation. The Procter & Gamble Company; New Chapter, Inc.; The Procter & Gamble Company. For Further Information Contact: Renee Chapman, Contact Representative, or Theresa Kingsberry, Legal Assistant, Federal Trade Commission, Premerger Notification Office, Bureau Of Competition, Room H–303, Washington, DC 20580, (202) 326–3100. By Direction of the Commission. Donald S. Clark, Secretary. [FR Doc. 2012–8734 Filed 4–12–12; 8:45 am] BILLING CODE 6750–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES pmangrum on DSK3VPTVN1PROD with NOTICES Office of the Secretary Findings of Research Misconduct Office of the Secretary, HHS. Notice. AGENCY: ACTION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: SUMMARY: VerDate Mar<15>2010 14:16 Apr 12, 2012 Jkt 226001 Peter J. Francis, M.D., Ph.D., Oregon Health Sciences University: Based on the report of an investigation conducted by Oregon Health Sciences University (OHSU) and additional analysis conducted by ORI in its oversight review, ORI found that Dr. Peter J. Francis, Associate Professor, Casey Eye Institute, OHSU, engaged in research misconduct in research reported in two grant applications, R01 EY021214–01 and resubmitted as R01 EY021214– 01A1, that he submitted to the National Eye Institute (NEI), National Institutes of Health (NIH). Specifically, ORI finds that the Respondent fabricated results of a pilot experiment in which he claimed to have injected retinal pigment epithelial (RPE) cells obtained from Rhesus monkey embryonic stem cells (ECS) into a strain of rats (RCS) that develops retinal degeneration. Respondent claimed that after the injection of ECS-derived RPE cells 21 days postnatal, the rats were tested at day 60 postnatal for optomotor acuity, and that the retinal histology of eyes receiving ECS-derived RPE cells, compared to mock-injected controls, PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 showed enhanced photoreceptor preservation and no adverse effects. Respondent admitted that this experiment had not been conducted either by the time the original grant application had been submitted or by the time the later R01 EY021214–01A1 application was submitted. Dr. Francis has entered into a Voluntary Settlement Agreement (Agreement) and has voluntarily agreed for a period of two (2) years, beginning on March 29, 2012: (1) To have his research supervised; Respondent agrees to ensure that prior to the submission of an application for U.S. Public Health Service (PHS) support for a research project on which the Respondent’s participation is proposed and prior to Respondent’s participation in any capacity on PHSsupported research, the institution employing him must submit a plan for supervision of Respondent’s duties to ORI for approval; the plan for supervision must be designed to ensure the scientific integrity of Respondent’s research contribution; Respondent agrees that he shall not participate in any PHS-supported research after sixty E:\FR\FM\13APN1.SGM 13APN1 Federal Register / Vol. 77, No. 72 / Friday, April 13, 2012 / Notices (60) days from the effective date of this Agreement until such a supervision plan is submitted to and approved by ORI; Respondent agrees to maintain responsibility for compliance with the agreed upon supervision plan; (2) that this supervisory plan provided by any institution employing him shall provide assurance that each application for PHS funds, or report, manuscript, or abstract involving PHS supported research in which Respondent was involved was based on actual experiments or was otherwise legitimately derived, that the data, procedures, and methodology were accurately reported in the application, report, manuscript, or abstract, and that the text in such submissions was his own or properly cited the source of copied language and ideas; and (3) to exclude himself from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800. John Dahlberg, Director, Division of Investigative Oversight, Office of Research Integrity. [FR Doc. 2012–8903 Filed 4–12–12; 8:45 am] BILLING CODE 4150–31–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the President’s Council on Fitness, Sports, and Nutrition Department of Health and Human Services, Office of the Secretary, Office of the Assistant Secretary for Health, Office of the President’s Council on Fitness, Sports, and Nutrition. ACTION: Notice of meeting. AGENCY: As stipulated by the Federal Advisory Committee Act, the U.S. Department of Health and Human Services (DHHS) is hereby giving notice that the President’s Council on Fitness, Sports, and Nutrition (PCFSN) will hold a meeting. The meeting will be open to the public. DATES: The meeting will be held on May 1, 2012, from 10 a.m. to 3 p.m. ADDRESSES: Department of Health and Human Services, 200 Independence Ave. SW., Room 800, Washington, DC 20201. FOR FURTHER INFORMATION CONTACT: Ms. Shellie Pfohl, Executive Director, President’s Council on Fitness, Sports, pmangrum on DSK3VPTVN1PROD with NOTICES SUMMARY: VerDate Mar<15>2010 14:16 Apr 12, 2012 Jkt 226001 and Nutrition, Tower Building, 1101 Wootton Parkway, Suite 560, Rockville, MD 20852, (240) 276–9866. Information about PCFSN, including details about the upcoming meeting, can be obtained at www.fitness.gov and/or by calling (240) 276–9567. SUPPLEMENTARY INFORMATION: On June 23, 2010, the President established Executive Order 13545 to amend Executive Order 13265, dated June 6, 2002. Under Executive Order 13545, direction is given for the scope of the President’s Council on Physical Fitness and Sports to be expanded to recognize that good nutrition goes hand in hand with fitness and sports participation. Executive Order 13545 gives authority for the title of the Council to be revised to include nutrition. The primary functions of the PCFSN include (1) Advising the President, through the Secretary, concerning progress made in carrying out the provisions of Executive Order 13545 and shall recommend to the President, through the Secretary, actions to accelerate progress; (2) advising the Secretary on ways to promote regular physical activity, fitness, sports participation, and good nutrition. Recommendations may address, but are not necessarily limited to, public awareness campaigns; Federal, State, and local physical activity; fitness, sports participation, and nutrition initiatives; and partnership opportunities between public- and private-sector health promotion entities; (3) functioning as a liaison to relevant State, local, and private entities in order to advise the Secretary regarding opportunities to extend and improve physical activity, fitness, sports, and nutrition programs and services at the local, State, and national levels; and (4) monitoring the need to enhance programs and educational and promotional materials sponsored, overseen, or disseminated by the Council, and shall advise the Secretary, as necessary, concerning such need. In performing its functions, the Council shall take into account the Federal Dietary Guidelines for Americans and the Physical Activity Guidelines for Americans. The PCFSN will hold, at a minimum, one meeting in a calendar year. The meeting will be held to (1) assess ongoing Council activities and (2) discuss and plan future projects and programs. The agenda for the planned meeting is being developed and will be posted at www.fitness.gov when it has been finalized. The meeting that is scheduled to be held May 1, 2012 is open to the public. PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 22321 Every effort will be made to provide reasonable accommodations for persons with disabilities and/or special needs who wish to attend the meeting. Persons with disabilities and/or special needs should call (240) 276–9567 no later than close of business on April 23, 2012, to request accommodations. Members of the public who wish to attend the meeting are asked to pre-register by calling (240) 276–9567. Registration for public attendance must be completed before close of business on April 23, 2012. Dated: March 9, 2012. Shellie Y. Pfohl, Executive Director, President’s Council on Fitness, Sports, and Nutrition. [FR Doc. 2012–8900 Filed 4–12–12; 8:45 am] BILLING CODE 4150–35–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods: Call for Nominations of High Throughput Screening (HTS) Assays for the Tox21 Initiative Division of the National Toxicology Program (DNTP), National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH). ACTION: Call for nominations. AGENCY: The multiagency Tox21 Initiative aims to improve hazard assessment of compounds potentially harmful to humans and the environment. This will be accomplished through the use of integrated high throughput screens that provide information on the ability of a substance to perturb biological pathways related to toxicity. On behalf of the Tox21 Consortium and its Assays and Pathways Working Group, the NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) is accepting nominations for HTS biochemical- or cell-based assays. Assays selected for further evaluation and found to be compatible with the HTS program will support Tox21 by providing data on endpoints that serve as markers for initiating or downstream events in toxicity pathways. SUMMARY: The nomination of HTS assays to Tox21 is an ongoing process and will continue to remain open. Periodic updates to this notice may be posted to reflect new focus areas of the Tox21 HTS program. DATES: E:\FR\FM\13APN1.SGM 13APN1

Agencies

[Federal Register Volume 77, Number 72 (Friday, April 13, 2012)]
[Notices]
[Pages 22320-22321]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-8903]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case:
    Peter J. Francis, M.D., Ph.D., Oregon Health Sciences University: 
Based on the report of an investigation conducted by Oregon Health 
Sciences University (OHSU) and additional analysis conducted by ORI in 
its oversight review, ORI found that Dr. Peter J. Francis, Associate 
Professor, Casey Eye Institute, OHSU, engaged in research misconduct in 
research reported in two grant applications, R01 EY021214-01 and 
resubmitted as R01 EY021214-01A1, that he submitted to the National Eye 
Institute (NEI), National Institutes of Health (NIH).
    Specifically, ORI finds that the Respondent fabricated results of a 
pilot experiment in which he claimed to have injected retinal pigment 
epithelial (RPE) cells obtained from Rhesus monkey embryonic stem cells 
(ECS) into a strain of rats (RCS) that develops retinal degeneration.
    Respondent claimed that after the injection of ECS-derived RPE 
cells 21 days postnatal, the rats were tested at day 60 postnatal for 
optomotor acuity, and that the retinal histology of eyes receiving ECS-
derived RPE cells, compared to mock-injected controls, showed enhanced 
photoreceptor preservation and no adverse effects. Respondent admitted 
that this experiment had not been conducted either by the time the 
original grant application had been submitted or by the time the later 
R01 EY021214-01A1 application was submitted.
    Dr. Francis has entered into a Voluntary Settlement Agreement 
(Agreement) and has voluntarily agreed for a period of two (2) years, 
beginning on March 29, 2012:
    (1) To have his research supervised; Respondent agrees to ensure 
that prior to the submission of an application for U.S. Public Health 
Service (PHS) support for a research project on which the Respondent's 
participation is proposed and prior to Respondent's participation in 
any capacity on PHS-supported research, the institution employing him 
must submit a plan for supervision of Respondent's duties to ORI for 
approval; the plan for supervision must be designed to ensure the 
scientific integrity of Respondent's research contribution; Respondent 
agrees that he shall not participate in any PHS-supported research 
after sixty

[[Page 22321]]

(60) days from the effective date of this Agreement until such a 
supervision plan is submitted to and approved by ORI; Respondent agrees 
to maintain responsibility for compliance with the agreed upon 
supervision plan;
    (2) that this supervisory plan provided by any institution 
employing him shall provide assurance that each application for PHS 
funds, or report, manuscript, or abstract involving PHS supported 
research in which Respondent was involved was based on actual 
experiments or was otherwise legitimately derived, that the data, 
procedures, and methodology were accurately reported in the 
application, report, manuscript, or abstract, and that the text in such 
submissions was his own or properly cited the source of copied language 
and ideas; and
    (3) to exclude himself from serving in any advisory capacity to PHS 
including, but not limited to, service on any PHS advisory committee, 
board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative 
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 
750, Rockville, MD 20852, (240) 453-8800.

John Dahlberg,
Director, Division of Investigative Oversight, Office of Research 
Integrity.
[FR Doc. 2012-8903 Filed 4-12-12; 8:45 am]
BILLING CODE 4150-31-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.